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Fatty liverThe liver plays a central role in regulating cholesterol homeostasis. High fat diets have been shown to induce
obesity and hyperlipidemia. Despite considerable advances in our understanding of cholesterol metabolism,
the regulation of liver cholesterol biosynthesis in response to high fat diet feeding has not been fully addressed.
The aim of the present study was to investigate mechanisms by which a high fat diet caused activation of liver
3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) leading to increased cholesterol
biosynthesis. Mice were fed a high fat diet (60% kcal fat) for 5 weeks. High fat diet feeding induced weight
gain and elevated lipid levels (total cholesterol and triglyceride) in both the liver and serum. Despite cholesterol
accumulation in the liver, there was a signiﬁcant increase in hepatic HMG-CoA reductase mRNA and protein ex-
pression as well as enzyme activity. The DNA binding activity of sterol regulatory element binding protein
(SREBP)-2 and speciﬁc protein 1 (Sp1) were also increased in the liver of mice fed a high fat diet. To validate
the in vivo ﬁndings, HepG2 cells were treated with palmitic acid. Such a treatment activated SREBP-2 as well
as increased the mRNA and enzyme activity of HMG-CoA reductase leading to intracellular cholesterol accumu-
lation. Inhibition of Sp1 by siRNA transfection abolished palmitic acid-induced SREBP-2 and HMG-CoA reductase
mRNA expression. These results suggest that Sp1-mediated SREBP-2 activation contributes to high fat diet
induced HMG-CoA reductase activation and increased cholesterol biosynthesis. This may play a role in
liver cholesterol accumulation and hypercholesterolemia.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
High fat diets are associated with the development of chronic disor-
ders such as obesity, diabetes, hyperlipidemia and metabolic syndrome
[1–4]. Dietary fats can also modulate systemic lipids, increasing the risk
of coronary heart disease and nonalcoholic fatty liver disease (NAFLD)
[5–8]. NAFLD is regarded as a hepatic manifestation of the metabolic
syndrome and characterized by the excessive accumulation of lipids in
the liver [9]. While exogenous dietary fat likely contributes to hepatic
lipid accumulation, there is evidence to suggest that endogenous lipid
synthesis may also play an important role in NAFLD [10–12]. Lipidomic
assessment of liver biopsies has revealed elevated levels of both esteriﬁed
and non-esteriﬁed cholesterol in the liver of overweight patients withtory, CCARM, St. Boniface
g, Manitoba R2H 2A6, Canada.
l rights reserved.NAFLD [10]. Intriguingly, a paradoxical increase in hepatic 3-hydroxy-3-
methylglutaryl-CoA reductase (HMG-CoA reductase) mRNA expression
has been detected in the liver of obese patients with NAFLD [11]. In-
creased cholesterol biosynthesis has also been found in patients with
NAFLD independent of obesity [12]. Itwould appear, then, that in the con-
text of NAFLD, the conventional feedback regulation of sterols on hepatic
cholesterol synthesis may be dysfunctional. As the liver plays a central
role in regulating both hepatic and systemic cholesterol levels, themolec-
ular mechanism responsible for disrupting de novo cholesterol synthesis
during NAFLD warrants more comprehensive investigation.
When cholesterol homeostasis is perturbed due to increased
synthesis, cholesterol accumulation in the liver may occur and its level
in the blood may become elevated (in the form of lipoproteins). De
novo cholesterol synthesis is regulated by the rate-limiting enzyme,
HMG-CoA reductase, which converts HMG-CoA to mevalonate. Under
physiological conditions, HMG-CoA reductase activity is regulated by
multiple mechanisms. At the transcriptional level, expression of the
HMG-CoA reductase gene is regulated by the sterol regulatory element
binding proteins (SREBP). The SREBPs are a class of membrane bound
transcription factors that play a fundamental role in managing the
Table 1
Real-time PCR primer sequences.
Gene Accession number Primers
Mouse
HMG-CoA reductase NM_013134 5′-CAGGATGCAGCACAGAATGT-3′
5′-CTTTGCATGCTCCTTGAACA-3′
GAPDH NM_017008 5′-GCACAGTCAAGGCCGAGAAT-3′
5′-GCCTTCTCCATGGTGGTGAA-3′
SREBP-2 NM_033218 5′-GCTGGTTTGACTGGATGGTT-3′
5′-ACCTTTGGCGAGGTCTAGGT-3′
LDL receptor NM_001252658.1 5′-ACCCCTCAAGACAGATGGTC-3′
5′-CAGCCCAGCTTTGCTCTTAT-3′
SR-B1 NM_016741.2 5′-TGCTCAAGAATGTCCGCATA-3′
5′-CTCGTTTGGGTTGACCACTT-3′
ApoE NM_009696.3 5′-AACCGCTTCTGGGATTACCT-3′
5′-CAGTGCCGTCAGTTCTTGTG-3′
CYP7A1 NM_007824.2 5′-GCTAAGACGCACCTCGTGAT-3′
5′-AGGGCTCCTGATCATTTGAA-3′
CYP27A1 NM_024264.4 5′-CACTTCCTGCTGACCAATGA-3′
5′-CAGTGTGTTGGATGTCGTGTC-3′
Abcg5 NM_031884.1 5′-ATTATGTGCATCTTAGGCAGCTC-3′
5′-CGTAGGAGAAGCAGTCTTGGAA-3′
Abcg8 NM_026180.2 5′-TACACTTCCTGCTCGTGTGG-3′
5′-GATCCATGCAGGCACTATCC-3′
PCSK9 NM_153565.2 5′-TTGGATTGAGGCCATAGGAG-3′
5′-GACGGCATAGACACCCTCAC-3′
β-actin NM_007393.3 5′-GATCAAGATCATTGCTCCTCCT-3′
5′-AGGGTGTAAAACGCAGCTCA-3′
Insig-1 NM_153526.5 5′-TGCAGATCCAGCGGAATGT-3′
5′-CCAGGCGGAGGAGAAGATG-3′
Human
HMG-CoA reductase NM_000859 5′-CACCAAGAAGACAGCCTGAA-3′
5′-CATCCTCCACAAGACATTGC-3′
GAPDH NM_002046 5′-ATCATCCCTGCCTCTACTGG-3′
5′-GTCAGGTCCACCACTGACAC-3′
SREBP-2 NM_004599 5′-AGCAGTGGGACCATTCTGAC-3′
5′-TTCCTCAGAACGCCAGACTT-3′
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including SREBP-1a and SREBP-1c which are encoded from one gene
and SREBP-2which is encoded by another gene [14]. The liver expresses
each of the three SREBP isoforms, however, it is SREBP-2 which selec-
tively activates de novo cholesterol synthesis by inducing the expression
of HMG-CoA reductase as well as other pertinent enzymes of the
cholesterol biosynthesis pathway [15]. Under physiological conditions,
activation of SREBP-2 is regulated by cellular sterols including choles-
terol. When the cellular sterol level is elevated, SREBP-2 remains in
the endoplasmic reticulum (ER) [14,15]. On the other hand, when the
cellular sterol level is depleted, SREBP-2 is translocated from the ER
to the Golgi, a step that is critical for the maturation and subsequent
nuclear localization of SREBP-2 [13–15]. Once inside the nucleus,
SREBP-2 binds to a sterol regulatory element DNA segment to activate
the HMG-CoA reductase gene. High fat diet feeding has been used to
generate rodent models that display hyperlipidemia, adiposity, hyper-
glycemia and fatty liver [4,16–18]. Elevation of hepatic fatty acid and
cholesterol biosynthesis has been observed in rats fed a high fat diet,
while increased cholesterol biosynthesis has also been reported in fatty
acid perfused rat liver [5,19,20]. In a recent study, we have observed
that high fat diet feeding (60% kcal fat) induces oxidative stress and an
elevation of triglycerides and total cholesterol levels in mouse liver [4].
Regulation of HMG-CoA reductase activity is the primary approach
for controlling de novo cholesterol synthesis, while abnormal activation
can lead to hepatic cholesterol accumulation and hypercholesterolemia.
The aim of the present studywas to investigatemechanisms bywhich a
high fat diet caused activation of hepatic HMG-CoA reductase leading to
increased de novo cholesterol synthesis in mice.
2. Materials and methods
2.1. Animals and treatment
Male C57BL/6 mice aged 6 weeks were randomly divided into two
groups. Control mice received formula D12450B (Research Diets Inc.)
comprised of 10% kcal fat, 20% kcal protein, and 70% kcal carbohydrate.
The caloric density of the control diet was 3.85 kcal/g. To induce a
phenotypical model of obesity, another group of mice received the
high fat formula D12492 (Research Diets Inc.) containing 60% kcal fat,
20% kcal protein and 20% kcal carbohydrate. The caloric density of the
high fat diet was 5.24 kcal/g. The cholesterol content of the control
diet was 18 mg/kg and in the high fat diet was 300.8 mg/kg. Both
diets contained a blend of saturated,monounsaturated and polyunsatu-
rated fatty acids. All mice had free access to food and water and were
kept on a 12-hour light/12-hour dark cycle. Mice were sacriﬁced after
5 weeks on the above diets. Serum for measuring lipids was prepared
from one set of mice that were fasted overnight. The other analyses
were conducted in samples collected from non-fasted mice. Lipids in
the liver tissue were extracted according to the Folch method [21].
Total cholesterol and triglyceride levels in the liver tissue and in the
serum were determined using enzymatic kits (Wako Chemicals). All
procedures were performed in accordance with the Guide to the Care
and Use of Experimental Animals published by the Canadian Council
on Animal Care and approved by the University of Manitoba Protocol
Management and Review Committee.
2.2. Cell culture
HepG2 cells (American Type Culture Collection), a cell line derived
from human hepatoblastoma, were cultured in Dulbecco's modiﬁed
Eagle's medium supplemented with 10% fetal bovine serum. HepG2
cells are commonly used for studying the regulation of lipid metabolism
[22,23]. Palmitic acid (C16:0) (Sigma Aldrich), one of the most abundant
fatty acids in the high fat diet, was dissolved in 10% fatty acid-free bovine
serum albumin by gently shaking overnight at 37 °C prior to being added
to the culture medium [24].2.3. Real-time polymerase chain reaction (PCR) analysis
The mRNA levels of HMG-CoA reductase and SREBP-2 were deter-
mined by real-time PCR analysis using the iQ5 real-time PCR detection
system (Bio-Rad) and normalized with GAPDH or β-actin as previously
described [25]. In brief, total RNAs were isolated from the liver tissue
with QIAZOL reagent (Qiagen) speciﬁc for fatty tissues. Total RNA (2 μg)
was converted to cDNA by reverse transcription. The real-time PCR reac-
tion mixture contained 0.4 μM of 5′ and 3′ primers and 2 μl of cDNA
product in iQ-SYBR green supermix reagent (Bio-Rad). The mRNA ex-
pression was expressed as percentage change relative to the control.
The expression of several other genes was also evaluated. All primers
(Invitrogen) used in this study are listed in Table 1.2.4. Western immunoblotting analysis
The protein levels of HMG-CoA reductase were determined by
Western immunoblotting analysis. In brief, liver proteins (50 μg) were
separated by electrophoresis on a 10% SDS polyacrylamide gel. Proteins
in the gel were transferred to a nitrocellulose membrane. The mem-
brane was probed with an anti-HMG-CoA reductase polyclonal anti-
body (1:1000, Millipore). HRP-conjugated anti-IgG antibody (1:1000,
Cell Signaling Technology) was used as the secondary antibody. The
corresponding protein bands were visualized using enhanced chemilu-
minescence reagents and analyzed with a gel documentation system
(Bio-Rad Gel Doc1000). To determine SREBP-2 protein levels, nuclear
proteins were prepared from the liver tissue. Western immunoblotting
analysis was conducted by using an anti-SREBP-2 monoclonal antibody
(1:1000, Cayman Chemical Company). To conﬁrm the equal loading of
proteins for each sample, the same membranes were re-probed with
anti-β-actin monoclonal antibody (1:3000, Cell Signaling).
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The activity of HMG-CoA reductase was determined by radio-
isotope assay using [3-14C]HMG-CoA (PerkinElmer) as a substrate
[25,26]. In brief, the assay mixture contained liver microsomes
(0.15–0.25 mg proteins) or cell lysate (0.05 mg protein), 20 mM
glucose 6-phosphate, 2.5 mM NADP, 1 unit glucose-6-phosphate
dehydrogenase, 8 mM dithiothreitol, 1.2 mM EDTA, and 0.004 μCi
[3-14C]HMG-CoA (PerkinElmer) in a phosphate buffer (pH 7.4). The
reaction was carried out at 37 °C for 60 min (for liver microsomes)
or 30 min (for cells) followed by addition of mevalonolactone and
HCl. Radiolabeled HMG-CoA and mevalonolactone were separated
by thin-layer chromatography in chloroform-acetone (2:1, vol/vol).
The location of mevalanolactone on the chromatographic plate was
visualized after staining with iodine vapor. The radioactivity associated
with mevalonolactone was measured with a scintillation counter
[25,26].2.6. Electrophoretic mobility shift assay (EMSA)
To determine whether HMG-CoA reductase was regulated by
SREBP-2 and whether SREBP-2 was regulated by the Sp1 transcription
factor, both the SREBP/DNA binding activity and Sp1/DNA binding activ-
ity were measured by EMSA. In brief, nuclear proteins were prepared
from mouse liver as previously described [25,27,28]. Nuclear proteins
(10 μg) were incubated with excess 32P-end-labeled oligonucleotides
containing a consensus sequence speciﬁc for the SREBP/DNA binding
site (5′-GGATGTCCATATTAGGACATCT-3′) (Santa Cruz Biotechnolo-
gy) or a consensus sequence speciﬁc for the Sp1/DNA binding site
(5′-ATTCGATCGGGGCGGGGCGAG-3′) (Promega). The reaction mix-
ture was then separated in 6% nondenaturing polyacrylamide gel
and dried on a piece of ﬁlter paper followed by autoradiography.2.7. Transfection of cells with Sp1 siRNA
HepG2 cells were transfected with Sp1 siRNA duplex
oligoribonucleotides (Stealth RNAi™, Invitrogen) according to themanu-
facturer's instructions. For a negative control, cells were transfected with
Stealth™ RNAi negative control (Invitrogen) consisting of a scrambled
sequence that was unable to inhibit gene expression. At 48 h after trans-
fection, cellswere incubated for 6 h in the absence or presence of palmitic
acid (0.3 mM). At the end of incubation, total RNAs were isolated.
The mRNA levels of SREBP-2 mRNA and HMG-CoA reductase were
determined by real-time PCR analysis.2.8. Filipin staining
Filipin is a ﬂuorescent compound that binds to unesteriﬁed (free)
cholesterol. HepG2 cells were cultured, allowing overnight attach-
ment to cover slides. Following the treatment with palmitic acid,
cells were washed with staining buffer (150 mM NaCl, 5 mM KCl,
1 mM CaCl2, 20 mM HEPES pH 7.4, and 2 g/L glucose) and ﬁxed
with 3.6% formaldehyde in PBS for 20 min at room temperature.
The ﬁxed cells were washed again with staining buffer and incubated
with 50 μg/ml ﬁlipin in the dark at room temperature for 2 h. After
one ﬁnal washing with staining buffer, glycerine was used to ﬁx a
coverslip over cells. Fluorescence signals were captured by Olympus
IX2 ﬂuorescence microscope and Inﬁnity 3 camera [11].2.9. Statistical analysis
Results were analyzed by a two-tailed Student's t-test. P values
less than 0.05 were considered statistically signiﬁcant.3. Results
3.1. Hepatic lipid accumulation and activation of HMG-CoA reductase in
mice fed a high fat diet
Mice consuming a high fat diet for 5 weeks had gained more body
weight than those of the control group (Fig. 1A). There was a signif-
icant increase in triglyceride and total cholesterol levels in the serum
(Fig. 1B) aswell as in the liver tissue (Fig. 1C). Real-time PCR andWest-
ern immunoblotting analysis revealed that HMG-CoA reductase mRNA
and protein levels were signiﬁcantly elevated in the liver of mice fed a
high fat diet (Figs. 2A and B). In accordance, liver HMG-CoA reductase
activity was increased in high fat diet fed mice (Fig. 2C). These results
suggested that the de novo cholesterol synthesis was elevated in the
liver of mice in response to high fat diet feeding.
3.2. Transcriptional regulation of HMG-CoA reductase by SREBP-2
SREBP-2 is an important transcription factor that binds to the
promoter region of HMG-CoA reductase to regulate its gene ex-
pression. To investigate whether high fat diet induced HMG-CoA
reductase expression was mediated through the activation of this
transcription factor, nuclear proteins were prepared from the liver tissue.
The SREBP/DNA binding activity was determined by EMSA. The SREBP/
DNA binding activity was signiﬁcantly increased in the liver of mice fed
a high fat diet as compared to those fed a control diet (Fig. 3A). The
SREBP-2 mRNA and nuclear SREBP-2 protein levels were elevated in the
liver of mice fed a high fat diet (Figs. 3B and C). Sp1 is a transcription
factor that binds to the promoter region of SREBP-2 gene to regulate its
transcription. To determine whether Sp1 was involved in the activation
of SREBP-2, the DNA binding activity of Sp1 was determined by EMSA.
The Sp1/DNA binding activity was markedly increased in the liver of
mice fed a high fat diet (Fig. 4). Taken together, these results suggested
that Sp1-mediated SREBP-2 activation plays an important role in
upregulating liver HMG-CoA reductase expression during high fat
diet feeding.
3.3. Expression of other hepatic genes in mice fed a high fat diet
To investigate whether high fat diet feeding affected other metabolic
pathways that were involved in cholesterol homeostasis, the mRNA
levels of LDL receptor, proprotein convertase subtilisin/kexin type 9
(PCSK9), scavenger receptor B1(SR-B1), apolipoprotein E (ApoE), choles-
terol 7 alpha-hydroxylase (CYP7A1), sterol 27-hydroxylase (CYP27A1),
ATP-binding cassette transporter G5 (Abcg5), ATP-binding cassette trans-
porter G8 (Abcg8) and insulin induced gene-1 (Insig-1) were measured
(Fig. 5). The expression of LDL receptor was signiﬁcantly increased
in the liver of high fat diet fed mice, which indicated that increased
lipoprotein uptake via LDL receptor might also contribute to the eleva-
tion of hepatic cholesterol levels. The expression of hepatic PCSK9 was
also elevated. The expression of hepatic CYP7A1 was signiﬁcantly in-
creased in high fat diet fed mice, which suggested that the metabolism
of hepatic cholesterol to bile acid was elevated. It was reported that the
activation of SREBP-2 might also be related to the Insig/SCAP system
[29]. The Insig-1 mRNA was signiﬁcantly increased in the liver of mice
fed a high fat diet, suggesting that elevation of cholesterol in the liver
upon high fat feeding might contribute to the upregulation of sterol-
sensitive Insig-1 expression.
3.4. Effect of fatty acid on HMG-CoA reductase expression in HepG2 cells
To further investigate whether increased endogenous cholesterol
biosynthesis could contribute to intracellular cholesterol accumula-
tion, experiments were conducted in HepG2 cells. Since palmitic
acid (C16:0) is one of the most abundant free fatty acids in the high
fat diet, its effect on HMG-CoA reductase activation was examined.
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Fig. 1. Body weight, serum and liver lipid contents. Mice were fed a control diet or a high fat diet (HFD) for 5 weeks. (A) Body weight was measured at the start and at the end of the
5 week feeding period and shown in grams (g). *P b 0.05 compared with the control group (n = 13). Total cholesterol and triglyceride levels (B) in the serum as well as (C) in the
liver were determined. *P b 0.05 compared with the control group (n = 4). Results were expressed as mean ± SEM.
1563N. Wu et al. / Biochimica et Biophysica Acta 1832 (2013) 1560–1568Incubation of cells with palmitic acid resulted in a signiﬁcant increase
in HMG-CoA reductase mRNA expression (Fig. 6A) and the enzyme
activity (Fig. 6B). In accordance, there was a marked increase in intra-
cellular total cholesterol level (Fig. 7A). Intracellular free cholesterol
accumulation was further examined by Filipin staining. Cells treated
with palmitic acid displayed increased ﬂuorescent intensity as com-
pared to control cells (Fig. 7B), indicating intracellular accumulation of
free cholesterol upon incubation with palmitic acid. Taken together,
these results suggested that palmitic acid could stimulate HMG-CoA
reductase gene expression leading to increased cholesterol biosynthesis
and accumulation in HepG2 cells.3.5. Role of Sp1 in SREBP-2 mediated HMG-CoA reductase expression
To further conﬁrm that Sp1 activation could lead to increased
SREBP-2 expression and subsequently HMG-CoA reductase activa-
tion, siRNA transfection was conducted in HepG2 cells. Cells were
transiently transfected with Sp1 siRNA or a scrambled siRNA control.
Inhibition of Sp1 expression by Sp1 siRNA transfection resulted in a
signiﬁcant reduction of palmitic acid induced elevation of SREBP-2
mRNA expression (Fig. 8A). Inhibition of Sp1 expression also attenu-
ated palmitic acid induced HMG-CoA reductase expression (Fig. 8B).These results suggested that Sp1 played an important role in SREBP-2
mediated HMG-CoA reductase expression in hepatocytes.
4. Discussion
Despite increased fat intake from the diet, cholesterol biosynthesis
was found to be markedly elevated in the liver of mice fed a high fat
diet. The present study has identiﬁed a novel mechanism whereby
consumption of a high fat diet for 5 weeks induces HMG-CoA reductase
activation in the mouse liver. Our results have clearly demonstrated
that during high fat feeding, increased Sp1 mediated SREBP-2 expres-
sion up-regulates HMG-CoA reductase leading to elevated cholesterol
biosynthesis in the liver.
Cholesterol is derived from the diet and from de novo synthesis.
HMG-CoA reductase regulates the rate-limiting step in the cholesterol
biosynthesis pathway. Regulation of hepatic HMG-CoA reductase acti-
vation is essential for maintaining cholesterol homeostasis in the liver
as well as in the circulation. In the present study, mice fed a high fat
diet for 5 weeks displayed a signiﬁcant increase in HMG-CoA reductase
activity in the liver which corresponded with signiﬁcant elevations in
HMG-CoA reductase mRNA and protein levels. To further investigate
whether increased de novo cholesterol synthesis might have contributed
to cholesterol accumulation in the liver, experiments were conducted in
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Fig. 2. Liver HMG-CoA reductase expression and enzyme activity in the liver tissue. Mice were fed a control diet or a high fat diet (HFD) for 5 weeks and livers were isolated. (A) The
HMG-CoA reductase mRNA levels with either GAPDH or β-actin as the internal control were determined by real-time PCR analysis (n = 10). (B) Total proteins in the liver tissue
were prepared and HMG-CoA reductase was measured by Western immunoblotting analysis with β-actin as the internal control (n = 10). In one set of experiments, the micro-
somal fraction was prepared from the liver tissue of control and high fat diet fed mice. HMG-CoA reductase protein in the microsomal fraction was analyzed by Western immuno-
blotting (n = 5). (C) HMG-CoA reductase enzyme activity was measured (n = 10). Results are expressed as mean ± SEM. *P b 0.05 when compared with the control value.
1564 N. Wu et al. / Biochimica et Biophysica Acta 1832 (2013) 1560–1568HepG2 cells. Incubation of cells with palmitic acid, one of the major fatty
acids in the high fat diet, resulted in upregulation of HMG-CoA reductase
expression and activation of the enzyme followed by a rise in cellular
cholesterol levels. In accordance with the observation in the liver of
mice fed a high fat diet, the expression of HMG-CoA reductase mRNA
was also signiﬁcantly elevated in cells incubated with palmitic acid. The
activation of HMG-CoA reductase and the accumulation of intracellular
cholesterol occurred in the absence of excess cholesterol being added
to the culture medium. It was conceivable that induction of HMG-CoA
reductase expression could lead to increased cholesterol biosynthesis
and subsequently its accumulation in hepatocytes. Results from the pres-
ent study suggested that increased de novo cholesterol synthesis might
contribute to hepatic lipid accumulation following the consumption of a
high fat diet.
In the present study, the high fat diet consisted of high amount of fatty
acids (32.89% w/w) and cholesterol (0.03% w/w) while the control diet
consisted of fatty acids (4.14% w/w) and cholesterol (0.0018% w/w).Despite a 16-fold increase in the cholesterol content in the high fed diet
versus the control diet, hepatic cholesterol synthesis remained elevated
in high fat diet fed mice. The activation of HMG-CoA reductase in these
mice might be a metabolic response to the higher intake of dietary fatty
acids [5,20]. In fact, not onlywas the total dietary fatty acid higher relative
to the control diet, but the total amount of fatty acids was approximately
1000-fold higher than the amount of cholesterol (w/w) in the high fat
diet. Therefore, the results obtained from the present study cannot
rule out the possibility that (1) in the presence of fatty acid surplus,
the stimulatory effect of fatty acids on cholesterol biosynthesis may
take precedence over cholesterol feedback inhibition, and/or (2) regula-
tion of cholesterol synthesis by the negative feedback mechanism
(elevation of cellular cholesterol) may, in itself, be disrupted in the liver
as a consequence of high fat diet feeding. The contribution of individual
lipids in the high fat diet remains to be investigated in future studies.
The expression of the HMG-CoA reductase gene is transcriptionally
regulated by SREBP-2 [15]. Historically, de novo cholesterol synthesis
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tion [13,30,31]. In general, the precursor of SREBP-2 is anchored in the
ER as a complex with SREBP cleavage activating protein (SCAP) [13].
SCAP is an escort protein for the SREBP protein and it binds with other
ER-membrane proteins, such as Insig-1. The binding of SCAP/SREBP to
the Insig-1 protein in the ER is sterol-dependent leading to ER retention
of SCAP/SREBP when sterol levels are elevated [29]. Such retention in
the ER by Insig-1 limits SREBP-2 transport to the Golgi apparatus there-
by inhibiting its proteolytic processing into the truncated (mature)
SREBP-2 protein which enters the nucleus and binds to the speciﬁc
sterol regulatory element (SRE) DNA sequences of target genes. For in-
stance, under physiological conditions, in cellswith elevated cholesterol
levels, SREBP-2 remains in the ER [14,15,29]. In cells with lower sterol
levels, SREBP-2 is transported from the ERmembrane to theGolgi appa-
ratus where it is processed by proteolytic enzymes. The truncated
(mature) SREBP-2 protein enters the nucleus and binds to the speciﬁc
sterol regulatory element (SRE) DNA sequences of theHMG-CoA reduc-
tase gene to activate its expression and hence increase cholesterol
biosynthesis. In the present study, Insig-1 expression was signiﬁcantly
elevated in the liver of mice fed a high fat diet. The expression of Insig-1
gene is also regulated by SREBPs [32]. It has been reported that the induc-
tion of nuclear SREBP-1a or SREBP-2 in CHO cells results in a signiﬁcant
increase in Insig-1 mRNA [32]. In the present study, SREBP-2 activation
might have contributed to the increased Insig-1 expression in the liverof mice fed a high fat diet. On the other hand, the Insig-1 protein is re-
quired for the sterol-dependent retention of SCAP/SREBP complex in
the ER [29]. Elevation of Insig-1 expression would facilitate the retention
of SCAP/SREBP complex in the ER. However, in the liver of high fat fed
mice, the nuclear SREBP-2 protein levels remained elevated despite the
increased expression of Insig-1. Results from present study suggested
that activation of hepatic SREBP-2 might be a result of increased expres-
sion of both the SREBP-2 gene and protein.
Activation of SREBP-2 can be regulated at the transcriptional level by
transcription factors such as Sp1 [33,34]. It has been shown that Sp1
binds to the promoter region of SREBP-2 to upregulate its gene expres-
sion in rat hepatic stellate cells [34]. In the present study, Sp1 was acti-
vated in the liver of mice consuming a high fat diet. In accordance, the
expression of SREBP-2 mRNA was signiﬁcantly increased in the same
liver tissue. To conﬁrm a causative relationship between Sp1 mediated
SREBP-2 activation and upregulation of HMG-CoA reductase expres-
sion, additional experiments were conducted in HepG2 cells. Inhibition
of Sp1 gene expression by siRNA transfection effectively abolished
SREBP-2 and HMG-CoA reductase expression in palmitic acid-treated
HepG2 cells. Taken together, these results suggested that the transcrip-
tional regulation of de novo cholesterol synthesis might be disrupted by
a high fat diet. This, in turn, may contribute to the lipid associated met-
abolic abnormalities which underlie fatty liver and hyperlipidemia. In
accordance with our ﬁndings, a recent study has revealed an increased
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and demonstrated its associationwith hepatic cholesterol accumulation
as well as LDL-cholesterol [35]. Future investigations are warranted to0
1
2
3
4
5
6
7
8
Control Palmitic acid
To
ta
l c
el
lu
la
r c
ho
le
st
er
ol
(A)
*
(B)
Control Palmitic Acid 
P=0.008
(µ
g/m
g p
ro
tei
n)
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by a commercial kit. Results are expressed as mean ± SEM (n = 7). *P b 0.05 when com-
paredwith the control value. (B) Intracellular free cholesterol was visualized by Filipin stain-
ing (in blue).evaluate whether targeted inhibition of HMG-CoA reductase activation
in the liver is of therapeutic value inmetabolic disorders that are linked
to the excessive intake of dietary fats or NAFLD.
We must acknowledge that other mechanisms aside from those
directly involved in de novo cholesterol synthesis might also contribute
to the dysregulation of cholesterol metabolism in mice fed a high fat
diet. For instance the gene expression of CYP7A1, which encodes the
rate limiting enzyme in bile acid synthesis, was increased in the liver of
mice consuming a high fat diet. The conversion of cholesterol to bile
acid might be one of the compensatory responses to the accumulation
of cholesterol in the liver of mice fed a high fat diet. On the other hand,
the LDL receptor is responsible for the hepatic clearance of circulating
LDL-cholesterol. In the present study, the expression of LDL receptor
was increased in the liver ofmice consuming a high fat diet. Interestingly,
the expression of PCSK9, which was known to induce LDL receptor pro-
tein degradation [36], was also up-regulated in these same livers. It has
been shown that SREBP-2 is one of the major transcription factors regu-
lating PCSK9 expression in mice and hamsters [37,38]. It is plausible
that the activation of SREBP-2 during high fat feedingmight have contrib-
uted to increased PCSK9 expression, which could spare the further accu-
mulation of lipids in the liver via attenuating LDL receptor mediated lipid
uptake from the circulation. However, the mechanisms by which these
genes are upregulated as well as the interaction between LDL receptor
and PCSK9 expression during high fat feeding remain to be investigated
in future studies.
In conclusion, the novel ﬁndings of the present study are that a
high fat diet upregulates Sp1 mediated SREBP-2 expression leading
1568 N. Wu et al. / Biochimica et Biophysica Acta 1832 (2013) 1560–1568to increased HMG-CoA reductase expression in mouse liver. Activa-
tion of HMG-CoA reductase results in an increased cholesterol syn-
thesis which may contribute to liver cholesterol accumulation and
hypercholesterolemia. Identiﬁcation of molecular mechanisms that
are responsible for the increased de novo cholesterol synthesis may
lead to a better therapeutic approach to manage hepatic lipid accu-
mulation and hypercholesterolemia.
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